** Shares of drug developer Lipocine up 6.19% at $5.5 in premarket trading
** Administration of Oral brexanolone, co's drug for treating post-partum depression, was consistent with therapies effective in managing depression, anxiety, tremors, and seizures
**Oral brexanolone was well-tolerated in the Phase 1 study, with a safety profile consistent with previous clinical studies
** As of last close stock up 85.30% YTD
(Reporting by Khusbu Jena)
((Khusbu.Jena@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。